NASDAQ:GERN Geron (GERN) Stock Forecast, Price & News $3.60 0.00 (0.00%) (As of 12:27 PM ET) Add Compare Share Share Today's Range$3.51▼$3.6550-Day Range$1.97▼$3.6052-Week Range$1.18▼$3.84Volume4.99 million shsAverage Volume7.87 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Geron MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside37.4% Upside$5.00 Price TargetShort InterestHealthy4.54% of Shares Sold ShortDividend StrengthN/ASustainability-3.19Upright™ Environmental ScoreNews Sentiment-0.40Based on 4 Articles This WeekInsider TradingSelling Shares$191,800 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector599th out of 980 stocksPharmaceutical Preparations Industry300th out of 485 stocks 3.4 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Geron has a forecasted upside of 37.4% from its current price of $3.64.Amount of Analyst CoverageGeron has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.54% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Geron has recently decreased by 2.16%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -24.49% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -3.19. Previous Next 1.4 News and Social Media Coverage News SentimentGeron has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Geron this week, compared to 4 articles on an average week.Search Interest43 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 48% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,800.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Geron is held by insiders.Percentage Held by Institutions49.75% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.36) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 18.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Geron (NASDAQ:GERN) StockGeron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.Read More Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock News HeadlinesJune 2, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Hold Rating on Geron (GERN)June 2, 2023 | finance.yahoo.comGeron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS PatientsJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.June 1, 2023 | finance.yahoo.comGeron (GERN) Just Flashed Golden Cross Signal: Do You Buy?May 31, 2023 | seekingalpha.comGeron: Ready To Face The Competition With Imetelstat In Lower Risk Myelodysplastic SyndromesMay 25, 2023 | businesswire.comGeron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in ...May 25, 2023 | finance.yahoo.comGeron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3May 21, 2023 | americanbankingnews.comGeron Co. (NASDAQ:GERN) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.May 16, 2023 | americanbankingnews.comB. Riley Equities Analysts Reduce Earnings Estimates for Geron Co. (NASDAQ:GERN)May 16, 2023 | americanbankingnews.comFY2027 Earnings Forecast for Geron Co. Issued By Wedbush (NASDAQ:GERN)May 15, 2023 | markets.businessinsider.comGeron (GERN) Receives a Buy from Robert W. BairdMay 13, 2023 | americanbankingnews.comV Bryan Lawlis Sells 35,000 Shares of Geron Co. (NASDAQ:GERN) StockMay 12, 2023 | msn.comWedbush Reiterates Geron (GERN) Outperform RecommendationMay 12, 2023 | markets.businessinsider.comWedbush Sticks to Their Buy Rating for Geron (GERN)May 12, 2023 | finance.yahoo.comCompany News for May 12, 2023May 12, 2023 | finance.yahoo.comQ1 2023 Geron Corp Earnings CallMay 11, 2023 | markets.businessinsider.comGeron Corporation Q1 Loss beats estimatesMay 11, 2023 | msn.comUnusual Call Option Trade in Geron (GERN) Worth $74.25KMay 11, 2023 | finance.yahoo.comGeron (GERN) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finance.yahoo.comGeron (GERN) Reports Q1 Loss, Misses Revenue EstimatesMay 11, 2023 | finance.yahoo.comGeron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3May 11, 2023 | washingtonpost.comGeron: Q1 Earnings SnapshotMay 11, 2023 | finance.yahoo.comGeron Corporation Reports First Quarter 2023 Financial Results and Business HighlightsMay 10, 2023 | msn.comA Preview Of Geron's EarningsMay 10, 2023 | seekingalpha.comGeron: Updates Ahead Of Q1 2023 EarningsMay 9, 2023 | americanbankingnews.comGeron (GERN) Set to Announce Quarterly Earnings on ThursdaySee More Headlines GERN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Company Calendar Last Earnings5/11/2023Today6/05/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees69Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+38.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,900,000.00 Net Margins-30,349.19% Pretax Margin-30,349.19% Return on Equity-91.38% Return on Assets-55.21% Debt Debt-to-Equity Ratio0.16 Current Ratio8.81 Quick Ratio8.81 Sales & Book Value Annual Sales$600,000.00 Price / Sales3,052.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book5.63Miscellaneous Outstanding Shares508,770,000Free Float492,995,000Market Cap$1.83 billion OptionableOptionable Beta0.90 Key ExecutivesJohn A. ScarlettChairman, President & Chief Executive OfficerAndrew J. GrethleinChief Operating Officer & Executive Vice PresidentOlivia K. BloomChief Financial Officer, Treasurer & Executive VPFaye FellerChief Medical Officer & Executive Vice PresidentStephen N. RosenfieldSecretary, Chief Legal Officer & Executive VPKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsPutnam Investments LLCSold 81,056 shares on 5/22/2023Ownership: 0.033%American TrustBought 12,583 shares on 5/22/2023Ownership: 0.002%JPMorgan Chase & Co.Bought 76,895 shares on 5/18/2023Ownership: 0.065%New York State Common Retirement FundSold 62,135 shares on 5/18/2023Ownership: 0.038%Belpointe Asset Management LLCSold 24,844 shares on 5/16/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions GERN Stock - Frequently Asked Questions Should I buy or sell Geron stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price forecast for 2023? 5 brokers have issued 1-year target prices for Geron's stock. Their GERN share price forecasts range from $3.00 to $7.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 38.9% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2023? Geron's stock was trading at $2.42 on January 1st, 2023. Since then, GERN shares have increased by 48.8% and is now trading at $3.60. View the best growth stocks for 2023 here. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) issued its quarterly earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.14 million. Geron had a negative net margin of 30,349.19% and a negative trailing twelve-month return on equity of 91.38%. During the same quarter in the previous year, the firm posted ($0.09) EPS. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Principal Healthcare Innovators ETF (BTEC). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). What is Geron's stock symbol? Geron trades on the NASDAQ under the ticker symbol "GERN." Who are Geron's major shareholders? Geron's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.19%), State Street Corp (5.02%), Wellington Management Group LLP (2.16%), FMR LLC (1.60%), Geode Capital Management LLC (1.59%) and Fairmount Funds Management LLC (1.40%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Geron's stock price today? One share of GERN stock can currently be purchased for approximately $3.60. How much money does Geron make? Geron (NASDAQ:GERN) has a market capitalization of $1.83 billion and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-141,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. How can I contact Geron? Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750. This page (NASDAQ:GERN) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.